For example, patients with metastatic colorectal cancer, who are wild-type for both RAS and BRAF genes, are the best-suited candidates for anti-epidermal growth factor receptor treatment.[6,7] Initial therapy with cetuximab-based regimens showed benefits for RAS wild-type left-sided tumors in a meta-analysis of 3 randomized trials that directly compared chemotherapy with either cetuximab or bevacizumab.[10] Our patient received bevacizumab despite having RAS wild-type, left-sided tumor due to limitations in the public healthcare system in South Korea. The gene discussed is EGFR; the disease is neoplasm.